Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Justin F Bower

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Current Pharmaceutical Design|June 2, 2012
Using fragment-based technologies to target protein-protein interactionsJustin F Bower, Andrew Pannifer
Bioorganic & Medicinal Chemistry Letters|May 22, 2012
The design and synthesis of novel, potent and orally bioavailable N-aryl piperazine-1-carboxamide CCR2 antagonists with very high hERG selectivityJohn G Cumming, Justin F Bower, David Waterson, et al.
Bioorganic & Medicinal Chemistry Letters|February 3, 2005
Structure-guided design of pyrazolo[1,5-a]pyrimidines as inhibitors of human cyclin-dependent kinase 2Douglas S Williamson, Martin J Parratt, Justin F Bower, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Current Pharmaceutical Design|June 2, 2012
Using fragment-based technologies to target protein-protein interactionsJustin F Bower, Andrew Pannifer
Bioorganic & Medicinal Chemistry Letters|May 22, 2012
The design and synthesis of novel, potent and orally bioavailable N-aryl piperazine-1-carboxamide CCR2 antagonists with very high hERG selectivityJohn G Cumming, Justin F Bower, David Waterson, et al.
Bioorganic & Medicinal Chemistry Letters|February 3, 2005
Structure-guided design of pyrazolo[1,5-a]pyrimidines as inhibitors of human cyclin-dependent kinase 2Douglas S Williamson, Martin J Parratt, Justin F Bower, et al.
Pageof 1